J-STORIES – Researchers in Japan have managed to unveil how so-called “neo-self” antibodies are connected with a variety of complications during pregnancy and birth, including Graves’ disease and even infertility.
In May this year, a joint study between the University of Yamanashi and Teine Keijinkai Hospital found that neo-self antibodies are not only linked with infertility, but with endometriotic infertility, and repeated implantation failure. The following month, a research group including scientists from Kobe University announced that the antibodies are also involved in hypertension during pregnancy, and fetal growth restriction. Both were the first research results of their kind in the world.
These studies followed on from joint research between Kobe University and Osaka University in 2015 that discovered this novel type of autoantibody that is involved in thrombosis and other disorders.
Such research has become crucial in Japan, which is facing ever more severe issues of declining birthrate and shrinking population and overcoming complications during pregnancy and childbirth such as infertility and fetal growth restriction has been seen as an important medical challenge.
Although the way in which these diseases arise is still not well understood and effective treatments do not yet exist, Japanese researchers have now been able to show that a major factor behind them is the effect of these novel neo-self autoantibodies.
The purpose of antibodies produced by the human body is to eliminate bacteria, viruses, and other foreign substances from the human body. However, problems with the immune system can lead to the generation of abnormal molecules called “autoantibodies” that attack the body’s own cells and tissues.
Autoantibodies are thought to be a cause of autoimmune diseases such as collagen disease, polymyositis, and Graves’ disease.
The June study, which was led by Kenji Tanimura of Kobe University, Hideto Yamada of Teine Keijinkai Hospital, and Hisashi Arase of Osaka University’s Research Institute for Microbial Diseases, was based on the belief that neo-self antibodies may be deeply involved not just in infertility, but also in the inability to carry pregnancy to full term, such as repeated miscarriages and stillbirths.
Together with the University of Toyama, Okayama University, the University of Tokyo, and Hyogo Medical University, they conducted sampling and undertook research to show the relationship between neo-self antibodies and infertility.
According to Tanimura, some women hoping to give birth suffer 10 or more miscarriages. Research has shown that around one in four women who are unable to carry babies to term are positive for neo-self antibodies, meaning it is possible that these antibodies are a significant cause of infertility.
For the research published this June, blood samples were taken from women receiving care at five hospitals in Japan, including four university hospitals. The women were in three groups: women with an inability to continue pregnancy to term; women who had gestational hypertension, fetal growth restriction, or premature delivery during a past pregnancy; and women who had delivered normal-sized babies with no pre-existing medical conditions or obstetric abnormalities. The rates of positive test for neo-self antibodies were then compared between the groups.
Even after accounting for other factors that might be involved in hypertension and fetal growth restriction, such as age, body mass index, and smoking, a clear association with testing positive for neo-self antibodies was found, said Tanimura.
The number of medical institutions in Japan that offer neo-self antibody testing is now on the increase. Tanimura told J-Stories that he hopes to present results of research into a treatment for women with infertility and provide evidence of its efficacy through clinical trials and other means over the next few years.
“Research into neo-self antibodies is not just [important for] obstetrics,”Tanimura said. “It is also the key to solving the mysteries of various autoimmune diseases such as rheumatoid arthritis and Graves’ disease. It could bring revolutionary developments in the field of immunology such as vaccines based on new ideas, which could be used to treat these diseases.”
Translation by Tony McNicol
Top page photo by envato
For inquiries about this article, please contact jstories@pacficbridge.jp
Click here for the Japanese version of the article.
